- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01962922
Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.
Prospective, Rand, Open-label, Single-center, 2 Sequence, 3 Period Crossover Study to Compare the Steady State PK of Once-Daily-Extended Release LCP-Tacro to Generic Tacrolimus Capsules Twice Daily in Stable A A Renal Transplant pt.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is open label, prospective, single-center, randomized, two sequence, three period crossover study to compare the steady state pharmacokinetics of once daily dosing of LCP-Tacro tablets to tacrolimus capsules administered twice daily in stable African American kidney transplant patients.
Approximately 72 male and female African American renal transplant patients on table immunosuppression regimens will be randomly assigned in a 1:1 ratio to one of two sequences:
Sequence 1: (n=36) 18 patients requiring less than 0.15 mg/kg/day and 18 patients requiring equal to or greater than 0.15 mg/kg/day. Patients will continue on generic tacrolimus capsules on days 1-7 (24 hours PK profile on day 7) then patients are switched to LCP-Tacro tablets (at 15% lower dose of twice daily generic tacrolimus) on day 8.
Sequence 2: (n=36) 18 patients requiring less than 0.15 mg/kg/day and 18 patients requiring equal to or greater than 0.15 mg/kg/day. Patients will receive LCP-Tacro tablets (at 15% lower dose than generic tacrolimus twice daily formulation) on days 1-7 (24 hour PK profile on day 7) patients are switched back to twice daily generic tacrolimus treatment beginning on day 8.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois, Chicago
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washingto University School of Medicine
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Age ≥18-80 old, male or female
- African Americans
- Willing to give written informed consent and to comply with study visits and restrictions, including being able to speak, write and understand English
- Pt who have received a primary or secondary transplant
- Pt least 6 (six) mth post-transplant and on a stable dose of tacrolimus
- BMI ≥19
- Pt who are sero-positive for Hepatitis B or C positive may also be enrolled
- Pt maintained on concurrent immunosuppression with stable doses during screening
- Pt on a proton PPI remain on the same PPI formulation and dose during the PK portion of the study.
- During PK phase Only: Pt taking any medication that could interfere with tacrolimus blood levels, including prescription and over-the-counter medications, herbal or food supplements (including grapefruit, and pomegranate products), or medications must continue the same dose and are willing to continue the same dose/routine
- During PK phase Only: the patient is not scheduled to begin any new medication that could interfere with tacrolimus blood levels, including prescription and over-the-counter medications, herbal or food
Exclusion Criteria:
- Evidence of acute rejection episode within the past three months
- Pt not Africa-American
- Recipients of organ transplants other than kidney
- Known to be HIV positive at transplant
- Pt with recurrent focal segmental glomerulosclerosis (FSGS)
- Pt with any severe medical condition (including infection) requiring acute or chronic treatment
- Pt with a positive DSA
- Pt with a positive BK virus results
- GFR < 25 ml/min measured by MDRD4 as SOC within last 30 days
- Patients with AST, ALT, total bilirubin > 2.5 x ULN or evidence of severe liver disease
- Pt with WBC < to 2000/mm3 or ANC < to 1500 mm3 with PLT < 75,000/mm3 or HGB < 8 g/dl
- Pt with mental or physical conditions or known non-adherence
- Presence of intractable immunosuppressant complications of side effects resulting in dose adjustment of tacrolimus
- Exposed to investigational therapy within 30 days prior to enrollment
- No anticipated changes in the immunosuppressive regimen, other than those specified by the study protocol
- Pt with severe diabetic gastroparesis or other severe GI disturbances
- Pt who have underwent gastric banding or gastric bypass at any time pre or post-transplant
- Pregnant or nursing (lactating) women, or planning to become pregnant
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant who are unwilling to use a defined SOC of method
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: LCP-Tacro
Envarsus XR
|
once-daily extended release tablet
Other Names:
|
ACTIVE_COMPARATOR: Tacrolimus - IR
Tacrolimus
|
twice daily capsules
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of AUC(0-24) for Envarsus XR and IR-Tac
Time Frame: Day 7
|
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours. |
Day 7
|
Evaluation of C(Max) for Envarsus XR and IR-Tac
Time Frame: Day 7
|
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours. |
Day 7
|
Evaluation of C(Min) for Envarsus XR and IR-Tac
Time Frame: Day 7
|
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours. |
Day 7
|
Evaluation of AUC(0-24) for Envarsus XR and IR-Tac
Time Frame: Day 14
|
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours. |
Day 14
|
Evaluation of C(Max) for Envarsus XR and IR-Tac
Time Frame: Day 14
|
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours. |
Day 14
|
Evaluation of C(Min) for Envarsus XR and IR-Tac
Time Frame: Day 14
|
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours |
Day 14
|
Evaluation of AUC(0-24) for Envarsus XR and IR-Tac
Time Frame: Day 21
|
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours. |
Day 21
|
Evaluation of C(Max) for Envarsus XR and IR-Tac
Time Frame: Day 21
|
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours. |
Day 21
|
Evaluation of C(Min) for Envarsus XR and IR-Tac
Time Frame: Day 21
|
Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below. Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours. |
Day 21
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Leslie Callahan, RN, Veloxis Pharmaceuticals
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCP-Tacro 3004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Failure
-
University of Sao Paulo General HospitalUnknownRenal Transplant Rejection | Graft Failure | Transplant; Failure, Kidney | Chronic Renal Failure (CRF)Brazil
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
Washington University School of MedicineCompletedAcute Renal Failure | Chronic Renal FailureUnited States
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Puerto Rico
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Canada
-
University Hospital, Clermont-FerrandRecruitingAcute Kidney Injury | Transient Acute Renal Failure | Persistent Acute Renal FailureFrance
-
University Hospital, GhentCompletedAcute Renal Failure | Chronic Renal FailureBelgium
-
The University of Hong KongHospital Authority, Hong KongCompletedEnd-stage Renal Failure (ESRF)Hong Kong
-
PfizerCompletedChronic Renal Failure Requiring HemodialysisUnited States, Puerto Rico
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompletedPalliative Care | Renal Failure, End-stageHong Kong
Clinical Trials on LCP-Tacro
-
Veloxis PharmaceuticalsCTI Clinical Trial and Consulting Services; AptuitCompletedRenal Failure | Kidney FailureUnited States
-
Veloxis PharmaceuticalsCompletedRenal Failure | TremorsUnited States
-
Regional Palliative Care NetworkCompleted
-
Veloxis PharmaceuticalsCTI Clinical Trial and Consulting ServicesCompleted
-
Lorenzo GallonCompletedEnd Stage Renal Disease | Rejection of Renal TransplantUnited States
-
Veloxis PharmaceuticalsCompleted
-
University Hospital, AkerUniversity of OsloCompletedProximal Humeral Fracture | Osteosynthesis or Conservative TreatmentNorway
-
Veloxis PharmaceuticalsCTI Clinical Trial and Consulting ServicesCompleted
-
Veloxis PharmaceuticalsCTI Clinical Trial and Consulting Services; AptuitCompletedLiver FailureUnited States
-
Veloxis PharmaceuticalsPPDCompleted